Carrier 62MC Manuale Utente

A Current Review of Targeted Therapeutics for Ovarian Cancer (Article begins on next page)The Harvard community has made this article openly availab

Journal of Oncology 9[30] H. F. Dvorak, “Vascular permeability factor/vascularendothelial growth factor: a critical cytokine in tumorangiogenesis and

10 Journal of Oncologylung cancer,” Journal of Clinical Oncology, vol. 23, no. 11, pp.2544–2555, 2005.[58] J. Andrae, R. Gallini, and C. Betsholtz, “R

Journal of Oncology 11[88] E. A. Harrington, D. Bebbington, J. Moore, et al., “VX-680,a potent and selective small-molecule inhibitor of the Aurorakin

Hindawi Publishing CorporationJournal of OncologyVolume 2010, Article ID 149362, 11 pagesdoi:10.1155/2010/149362Review A rticleA Current Review of Tar

2 Journal of Oncologyconventional cytotoxic agents that target VEGF have takencenter stage.Agents targeting angiogenesis include monoclonal anti-bodie

Journal of Oncology 3Table 1: Current trials in ovarian/fallopian/peritoneal cancer.Author N Prior lines Platinum S/R∗/first line Regimen∗∗RR:CR + PR T

4 Journal of Oncologyovarian cancer was conducted. Five partial responses in asample size of 45 patients (11%) were reported.5. Epidermal Growth Facto

Journal of Oncology 5Table 2: PDGF-targeted therapies in ovarian cancer.clinical trial.gov IDTherapeutic regimenStudy PINCT00913835Doxil± IMC 3G3 in p

6 Journal of OncologyTable 3: α-folate receptor inhibitors and ovarian cancer.Clinical trial.gov ID Therapeutic regimen Study PINCT00722592 Doxil and

Journal of Oncology 7Table 4: PARP inhibitors and ovarian cancer.clinical trial.gov ID Therapeutic regimen Study PINCT00753545 AZD2281 in platinum sen

8 Journal of Oncology[2] M. S Gordon, D. Matei, C. Aghajanian, et al., “Clinical activ-ity of pertuzumab (rhuMab 2C4) in advanced, refractoryor recurr